Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment.

Details

• Alternative Title:
  AIDS (London, England), 2025, v. 39, no. 10: Longer-acting Preexposure Prophylaxis Product and Delivery Preferences Among U.S. Populations Disproportionately Affected by HIV: a Discrete Choice Experiment.
• Journal Article:
  AIDS (London, England)
• Personal Author:
  Roberts, Sarah T. ; Browne, Erica N. ; Denson, Damian ; Moore, Emily ; Mungo, Jackie ; Mancuso, Noah ; Diaz, Miranda ; Patel, Rupa ; Kourtis, Athena P. ; Minnis, Alexandra M. ; Hoover, Karen W.
• Description:
  Longer-acting preexposure prophylaxis (LA-PrEP) products have potential to increase PrEP uptake and continuation. This study sought to elicit preferences for LA-PrEP product and delivery program characteristics among populations disproportionately impacted by HIV to identify factors important to adoption and anticipate potential use challenges.
  
  Cross-sectional, online discrete choice experiment.
  
  We recruited 940 men who have sex with men (MSM), people who inject drugs (PWID), and Black heterosexual men and women (BHMW) with PrEP indications. In a series of 10 tasks, participants chose between two hypothetical LA-PrEP options composed of 5 attributes (product type, side effects, clinic type, appointment duration, cost), or neither (their current HIV prevention method). Analysis used random-parameters logit models.
  
  Respondents chose an LA-PrEP method over their current HIV prevention option in 96.8% of tasks. Cost was the most important determinant of LA-PrEP choice for all populations (relative importance RI of 10. Side effects and product type were 1/3 to 1/2 as important as cost (RI 3.5-5.1). MSM and PWID most preferred the 12-month implant followed by semiannual dual injections and least preferred the monthly oral pill and 2-month single injection. BHMW most preferred the monthly pill and semiannual injections and least preferred the 12-month implant and 2-month injection. Clinic type and appointment duration had minimal influence (RI 0.1-2.1).
  
  Results suggest high demand for LA-PrEP among populations with disproportionately high HIV incidence. To facilitate use, programs should offer a range of LA-PrEP products, minimize out-of-pocket costs, and counsel on side effects.
• Content Notes:
  Author manuscript
• Subjects:
  • Humans
  • Pre-Exposure Prophylaxis
  • HIV Infections
  • Male
  • Cross-Sectional Studies
  • Female
  • Adult
  • Middle Aged
  • Young Adult
  • Anti-HIV Agents
  More +
• Keywords:
  • black heterosexual men and women
  • discrete choice experiment
  • HIV prevention
  • longer-acting preexposure prophylaxis
  • men who have sex with men
  • people who inject drugs
• Source:
  AIDS (London, England), 2025, v. 39, no. 10
• DOI:
  https://doi.org/10.1097/QAD.0000000000004247
• ISSN:
  0269-9370 ; 1473-5571
• Pubmed ID:
  40424538
• Pubmed Central ID:
  PMC12459700
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  1364-1374 (18 pdf pages)
• Volume:
  39
• Issue:
  10
• Download URL:
  https://stacks.cdc.gov/view/cdc/261382/cdc_261382_DS1.pdf
• File Type:
  [PDF - 803.68 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:8128ae36485aabe5cfb2b1684044a6c2deda26568d7a12c0e89359ecc893cb54164983ff16ac86f1b0e6cdafa4144bb27e2d664951e22ba03dda70292e252551